- Home
- CHRS vs VERI Comparison
CHRS vs VERI Comparison
Compare CHRS & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- VERI
- Stock Information
- Founded
- CHRS 2010
- VERI 2014
- Country
- CHRS United States
- VERI United States
- Employees
- CHRS N/A
- VERI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- VERI EDP Services
- Sector
- CHRS Health Care
- VERI Technology
- Exchange
- CHRS Nasdaq
- VERI Nasdaq
- Market Cap
- CHRS 100.9M
- VERI 112.7M
- IPO Year
- CHRS 2014
- VERI 2017
- Fundamental
- Price
- CHRS $1.10
- VERI $2.67
- Analyst Decision
- CHRS Strong Buy
- VERI Hold
- Analyst Count
- CHRS 4
- VERI 1
- Target Price
- CHRS $6.13
- VERI $2.25
- AVG Volume (30 Days)
- CHRS 3.1M
- VERI 729.7K
- Earning Date
- CHRS 11-06-2024
- VERI 11-12-2024
- Dividend Yield
- CHRS N/A
- VERI N/A
- EPS Growth
- CHRS N/A
- VERI N/A
- EPS
- CHRS N/A
- VERI N/A
- Revenue
- CHRS $304,340,000.00
- VERI $124,881,000.00
- Revenue This Year
- CHRS $3.33
- VERI $10.27
- Revenue Next Year
- CHRS $16.77
- VERI $2.47
- P/E Ratio
- CHRS N/A
- VERI N/A
- Revenue Growth
- CHRS 44.19
- VERI 6.94
- 52 Week Low
- CHRS $0.66
- VERI $1.48
- 52 Week High
- CHRS $3.70
- VERI $7.76
- Technical
- Relative Strength Index (RSI)
- CHRS 69.14
- VERI 37.01
- Support Level
- CHRS $0.70
- VERI $2.81
- Resistance Level
- CHRS $0.89
- VERI $3.80
- Average True Range (ATR)
- CHRS 0.10
- VERI 0.29
- MACD
- CHRS 0.04
- VERI -0.06
- Stochastic Oscillator
- CHRS 93.70
- VERI 4.24
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel and India.